![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/0/0d/Repotrectinib.svg/640px-Repotrectinib.svg.png&w=640&q=50)
Repotrectinib
Medication / From Wikipedia, the free encyclopedia
Repotrectinib, sold under the brand name Augtyro, is an anti-cancer medication used for the treatment of non-small cell lung cancer.[1][2] It is taken by mouth.[1] Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC.[1]
Quick Facts Clinical data, Trade names ...
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Augtyro |
Other names | TPX-0005 |
AHFS/Drugs.com | Augtyro |
License data | |
Routes of administration | By mouth |
Drug class | Tyrosine kinase inhibitor |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C18H18FN5O2 |
Molar mass | 355.373 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
The most common adverse reactions include dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, ataxia, fatigue, cognitive disorders, and muscular weakness.[2]
Repotrectinib was approved for medical use in the United States in November 2023.[2][3]